MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2018
At a glance
- Drugs Trastuzumab (Primary) ; Tucatinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms MOUNTAINEER
- 04 Jan 2018 According to a Cascadian Therapeutics media release, company plans to report interim results from this study during 2018.
- 20 Nov 2017 Planned number of patients changed from 35 to 25.
- 24 Oct 2017 Planned End Date changed from 30 Jun 2020 to 30 Jun 2019.